Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant

American Journal of Ophthalmology

Volumn 127, Issue 3, 1999, Pages 283-287

  Davis, Janet L ^a   Tabandeh, Homayoun ^a   Feuer, William J ^a   Kumbhat, Seema ^a   Roth, Daniel B ^a   Chaudhry, Nauman A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GANCICLOVIR;

ADULT; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT INFECTION; RETINITIS; T LYMPHOCYTE; VISUAL ACUITY;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; CYTOMEGALOVIRUS RETINITIS; DISEASE PROGRESSION; DRUG IMPLANTS; GANCICLOVIR; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VISUAL ACUITY;

EID: 0033106330     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00442-5     Document Type: Article

References (17)

1. Hoover D.R., Saah A.J., Bacellar H., et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med. 329:1993;1922-1926.
2. Jabs D.A., Bartlett J.G. AIDS and ophthalmology a period of transition. Am J Ophthalmol. 124:1997;227-233.
3. Roth D.B., Feuer W.J., Blenke A.J., Davis J.L. Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant. Am J Ophthalmol. 127:1999;276-282.
4. Carpenter C.C., Fischl M.A., Hammer S.M., et al. Antiretroviral therapy for HIV infection in 1998 updated recommendations of the International AIDS Society- USA panel. JAMA. 280:1998;78-86.
5. Condra J.H., Schleif W.A., Blahy O.M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
6. Centers for Disease Control and Prevention. Update trends and AIDS incidence, death, prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep. 46:1997;165-173.
7. Coombs R.W., Welles S.L., Hooper C., et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 174:1996;704-712.
8. Whitcup S.M., Fortin E., Nussenblatt R.B., Polis M.A., Muccioli C., Belfort R. Jr. Therapeutic effect of combination antiretroviral therapy on CMV retinitis. JAMA. 277:1997;1519-1520.
9. + counts. Ophthalmology. 105:1998;1259-1264.
10. Reed J.B., Schwab I.R., Gordon J., Morse L.S. Regression of CMV retinitis associated with protease inhibitor treatment of AIDS. Am J Ophthalmol. 124:1997;199-205.
11. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed CMV retinitis in patients with AIDS the CMV Retreatment Trial. Arch Ophthalmol. 114:1996;23-33.
12. Marx J.L., Kapusta M.A., Patel S.S., et al. Use of the ganciclovir implant in the treatment of recurrent CMV retinitis. Arch Ophthalmol. 114:1996;815-820.
13. Hatton M.P., Duker J.S., Reichel E., Morley M.G., Puliafito C.A. Treatment of relapsed CMV retinitis with the sustained-release ganciclovir implant. Retina. 18:1998;50-55.
14. Jacobson M.A., Zegans M., Pavan P.R., et al. CMV retinitis after highly active antiretroviral therapy. Lancet. 349:1997;1443-1445.
15. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy the end of opportunism? JAMA. 280:1998;72-77.
16. Whitley R.J., Jacobson M.A., Friedberg D.N., et al. Guidelines for the treatment of CMV diseases in patients with AIDS in the era of potent antiretroviral therapy recommendations of an international panel: International AIDS Society-USA. Arch Intern Med. 158:1998;957-969.
17. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 4:1998;953-956.